Related Experiment Video
Updated: Sep 13, 2025
Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model
Published on: April 6, 2022
Postbiotics as Mitochondrial Modulators in Inflammatory Bowel Disease: Mechanistic Insights and Therapeutic Potential
Santosh Kumar Prajapati1,2, Dhananjay Yadav1, Shweta Katiyar3
1USF Center for Microbiome Research, Microbiomes Institute, Morsani College of Medicine, University of South Florida, Tampa, FL 33602, USA.
Abstract:
Postbiotics, which are non-viable microbial derivatives including short-chain fatty acids (SCFAs), microbial peptides, and cell wall components, are emerging as novel therapeutic agents for Inflammatory Bowel Disease (IBD). Unlike probiotics, postbiotics offer a safer, more stable alternative while retaining potent bioactivity. IBD, encompassing Crohn's disease and ulcerative colitis, is characterized by chronic gastrointestinal inflammation, epithelial barrier dysfunction, and immune dysregulation. Recent evidence links mitochondrial dysfunction marked by impaired energy metabolism, oxidative stress, and apoptosis with the pathogenesis and persistence of IBD. Postbiotics have shown the ability to modulate mitochondrial health through multiple mechanisms. SCFAs such as butyrate serve as primary energy substrates for colonocytes, enhancing mitochondrial respiration and promoting biogenesis. They improve mitochondrial function and boost ATP production. Moreover, postbiotics reduce oxidative damage by regulating antioxidant defenses. These antioxidant actions limit epithelial apoptosis and preserve cellular integrity. In addition, postbiotics regulate mitophagy and help maintain mitochondrial quality and reduce inflammation. Structural components such as lipoteichoic acid and peptidoglycan have been shown to interact with mitochondrial pathways and modulate inflammatory responses. Collectively, this review explores the interplay between mitochondrial dysfunction, IBD, and preventive approach using postbiotics. Understanding the connections with postbiotics could open up new avenues for therapeutic interventions aimed at mitigating IBD severity in people with IBD.
Insights
Postbiotics, beneficial microbial byproducts, offer a safe and stable approach to managing Inflammatory Bowel Disease (IBD). They improve mitochondrial function, reduce oxidative stress, and enhance gut barrier integrity, presenting a novel therapeutic strategy.
Area of Science:
- Microbiology and Immunology
- Gastroenterology
- Mitochondrial Biology
Background:
- Inflammatory Bowel Disease (IBD), including Crohn's disease and ulcerative colitis, involves chronic gut inflammation, barrier defects, and immune imbalance.
- Mitochondrial dysfunction, characterized by impaired energy metabolism and oxidative stress, is increasingly implicated in IBD pathogenesis.
- Postbiotics, non-viable microbial derivatives, are emerging as safe and stable therapeutic agents for IBD.
Purpose of the Study:
- To explore the role of mitochondrial dysfunction in IBD.
- To investigate the potential of postbiotics in mitigating IBD through modulation of mitochondrial health.
- To review the therapeutic applications of postbiotics for IBD management.
Main Methods:
- Review of current scientific literature on postbiotics, IBD, and mitochondrial function.
- Analysis of mechanisms by which postbiotics influence mitochondrial respiration, antioxidant defense, and mitophagy.
- Examination of the impact of microbial components (SCFAs, lipoteichoic acid, peptidoglycan) on mitochondrial pathways.
Main Results:
- Short-chain fatty acids (SCFAs) like butyrate serve as energy substrates, enhancing mitochondrial respiration and ATP production.
- Postbiotics reduce oxidative stress, protecting epithelial cells from apoptosis and preserving barrier integrity.
- Postbiotics regulate mitophagy, maintaining mitochondrial quality and reducing inflammation; structural components modulate inflammatory responses.
Conclusions:
- Postbiotics demonstrate significant potential in improving mitochondrial health and function in the context of IBD.
- Their ability to enhance energy metabolism, reduce oxidative damage, and regulate mitophagy offers a promising therapeutic avenue.
- Understanding the interplay between postbiotics and mitochondrial pathways could lead to novel strategies for IBD treatment.
More Related Videos
08:58Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis
Published on: January 5, 2017
08:53Investigating the Alleviating Effects of Bacillus cereus Administration on Colitis through Gut Microbiota Modulation
Published on: July 27, 2022
Related Concept Videos
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
01:30Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
01:30Inflammatory Bowel Disease II: Crohn's Disease
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
01:17Irritable Bowel Syndrome I: Introduction
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF